By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists agree that while Lilly (LLY) has shown impressive growth and superior efficacy in weight loss, the market is overlooking significant risks such as patent cliffs, pricing pressure from PBMs, and supply constraints. Novo Nordisk (NVO) is also facing challenges but has a strong global manufacturing capacity and head start in oral formulations.
Risk: PBM squeeze and potential erosion of net pricing power
Opportunity: LLY's clinical edge and pipeline depth
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trials, and market expansion.
The Lawsuit: Misleading Ads vs. Scientific Evidence
Novo Nordisk A/S (NYSE:NVO)'s legal action centers on commercial advertisements aired during major broadcasts and social media platforms. Novo Nordisk claims that Eli Lilly's promotional campaigns intentionally use outdated trial data to pit the highest approved doses of Lilly's tirzepatide (Zepbound/Mounjaro) against lower, older doses of Novo's semaglutide (Wegovy/Ozempic). Novo argues these ads create consumer confusion by omitting Novo's recently approved higher-dose versions, demanding a permanent injunction to pull the ads and force Lilly to launch a corrective campaign.
Eli Lilly and Company (NYSE:LLY) fired back immediately, stating that its commercials are "truthful," "transparent," and grounded in direct scientific evidence. A spokesperson for Eli Lilly emphasized that the claims stem from the SURMOUNT-5 trial, which is a rigorous head-to-head clinical study directly comparing tirzepatide against semaglutide. Lilly asserted that rather than competing on product merits, Novo Nordisk is attempting to censor published trial results. Lilly confirmed it plans to defend itself "vigorously" in court.
Q1 2026 Financial Comparison: Lilly Takes the Lead
Both companies remain highly profitable, but Eli Lilly is currently demonstrating significantly faster top-line growth and stronger forward momentum based on their Q1 2026 financial results.
Eli Lilly and Company (NYSE:LLY)
Eli Lilly delivered exceptional growth in its Q1 2026 results, with revenue increasing 56% year-over-year to $19.8 billion. The growth was primarily driven by a 65% increase in sales volume, led by strong demand for its blockbuster GLP-1 medicines, Mounjaro and Zepbound.
The company also reported a significant improvement in profitability, with net income reaching $7.4 billion, or $8.26 per share, compared with $2.8 billion, or $3.06 per share, in Q1 2025. Non-GAAP EPS surged 156% to $8.55, reflecting strong operating leverage and robust commercial execution.
Supported by accelerating demand, Eli Lilly raised its full-year 2026 revenue guidance by $2 billion, increasing its expected revenue range to $82.0 billion–$85.0 billion. The company also lifted its non-GAAP EPS outlook to $35.50–$37.00, signaling continued confidence in its growth trajectory.
Novo Nordisk A/S (NYSE:NVO)
Novo Nordisk delivered solid headline growth in Q1 2026, but its results reflected a more complex operating environment. Net sales increased 32% year-over-year in constant exchange rates (CER) to DKK 96.82 billion ($13.8 billion). However, this growth was significantly impacted by a $4.2 billion non-recurring provision reversal related to the U.S. 340B Drug Pricing Program. Excluding this one-time benefit, adjusted sales declined 4% at CER due to lower realized prices in the U.S., despite continued volume growth in GLP-1 products.
Reported operating profit increased 65% in constant exchange rates to DKK 59.62 billion, although adjusted operating profit declined 6% at CER to DKK 32.86 billion, highlighting ongoing pricing and margin pressures.
Commercially, Novo Nordisk continued to advance its obesity franchise with the successful U.S. launch of the Wegovy oral pill, which generated DKK 2.26 billion in Q1 revenue. The company also received FDA approval for Wegovy HD (7.2 mg injection), which demonstrated nearly 21% mean weight loss in clinical trials, strengthening its long-term competitive position in the obesity treatment market.
Comparison: Which Company Is Doing Better?
Comparing the two companies, Eli Lilly is currently demonstrating stronger overall performance and momentum.
Eli Lilly's dual GIP/GLP-1 mechanism, tirzepatide, has consistently shown higher weight-loss outcomes in clinical data compared with standard semaglutide-based treatments. This clinical advantage is translating directly into financial performance, with the company delivering 56% organic revenue growth in Q1 2026 and increasing its full-year revenue guidance by $2 billion.
Novo Nordisk, while continuing to expand its obesity treatment portfolio through the launch of oral Wegovy and the approval of Wegovy HD, has faced greater pricing pressures in the U.S. market. After excluding the impact of the non-recurring 340B accounting adjustment, the company's underlying quarterly performance showed a 4% decline in adjusted revenue and a 6% decline in adjusted operating profit at constant exchange rates.
Insider Monkey Hedge Fund Data Analysis
Institutional data from Insider Monkey shows institutional positioning diverging between the two rivals. Eli Lilly maintained strong top-tier hedge fund backing, with 132 hedge funds holding shares in Q1 2026 compared to 137 funds in Q4 2025. Among the prominent holders, HealthInvest Partners AB (managed by Anders Hallberg and Carl Bennet) holds 29,821 shares valued at $35.77 million (representing 9.62% of their portfolio despite a 25% trim), while Bourgeon Capital(managed by John Zaro) increased its position by 5% to 24,426 shares valued at $29.30 million (4.31% of portfolio).
Novo Nordisk displays a significantly smaller hedge fund footprint, with holding concentration staying flat at 55 hedge funds in both Q1 2026 and Q4 2025. Notable institutional positions include Taproot Management (led by David Lin and Jason Beverage).
Conclusion
The legal feud between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY) reflects how high the stakes are in the metabolic market. While Novo Nordisk continues to produce stellar profits and dominant global volume, Eli Lilly is currently winning the momentum battle thanks to higher efficacy data, faster U.S. commercial traction, and higher hedge fund conviction. As supply bottlenecks ease for both players, future outperformance will depend less on legal squabbles over advertising disclaimers and more on who can deliver next-generation oral formulations to patients first.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.
Four leading AI models discuss this article
"Both stocks are expensive; the lawsuit and headline growth figures overstate Lilly’s sustainable lead once supply normalizes and Novo’s next-gen products hit the market."
The article's portrayal of LLY decisively pulling ahead on 56% revenue growth, SURMOUNT-5 data, and hedge-fund ownership is directionally correct but incomplete. Q1 2026 figures appear to be mislabeled (actual 2025 results were ~36% growth for LLY); Novo’s adjusted revenue decline is largely U.S. pricing pressure rather than demand weakness. Tirzepatide’s ~5-7 pt efficacy edge is real, yet Novo’s oral semaglutide launch and newly approved 7.2 mg Wegovy HD close the gap faster than the piece admits. Supply is still the binding constraint for both; legal noise is largely theater. Valuation gap (LLY ~58x 2026 EPS, NVO ~38x) already prices in much of Lilly’s momentum.
If Lilly cannot scale manufacturing to meet demand while Novo successfully rolls out its oral and higher-dose injectables, the clinical edge evaporates and Novo regains share at a cheaper multiple.
"LLY’s current premium valuation is predicated on sustained clinical superiority and flawless execution, leaving it highly vulnerable to margin compression if the legal and pricing environment in the U.S. shifts."
The narrative that LLY is 'winning' based on Q1 2026 growth is a classic case of confusing momentum with long-term durability. While LLY’s 56% revenue growth is impressive, it is heavily reliant on supply-constrained ramp-ups. NVO’s 'decline' in adjusted metrics is largely a function of U.S. pricing pressure and aggressive 340B rebate accounting, not a failure of demand. The market is ignoring the massive moat NVO has built in global manufacturing capacity and its head start in oral formulations. LLY’s valuation currently prices in perfection; any hiccup in manufacturing scaling or a negative legal ruling on their marketing practices could trigger a significant multiple compression.
If LLY’s dual GIP/GLP-1 mechanism maintains its clinical superiority in real-world outcomes, NVO may be forced into a permanent 'value' trap, constantly sacrificing margins to defend market share against a superior product.
"LLY has genuine clinical and commercial momentum, but the market is pricing in perfection; NVO's near-term pain masks a resilient franchise that could re-accelerate once U.S. pricing stabilizes and oral penetration ramps."
The article presents a clean LLY-outperforming-NVO narrative, but the underlying numbers are murkier than presented. LLY's 56% revenue growth is real, but NVO's 4% adjusted revenue decline excludes a $4.2B one-time 340B reversal—strip that out and NVO's organic GLP-1 volume growth remains solid. The lawsuit is noise; both companies will keep selling. The real risk: LLY's guidance assumes sustained 56%+ growth in a market where supply constraints are easing and competition is intensifying (oral formulations, new entrants). At current valuations, LLY prices in near-perfect execution. NVO's margin compression is concerning but temporary if pricing stabilizes.
LLY's forward guidance of $35.50–$37.00 non-GAAP EPS implies 156% growth sustainability—historically unsustainable for a $500B+ pharma company. If obesity market growth decelerates faster than expected or oral competitors (including NVO's Wegovy oral) erode tirzepatide's pricing power, LLY faces a significant multiple compression risk that the article entirely ignores.
"Lilly is gaining near-term momentum in the obesity GLP-1 market, but the durability of that lead depends on real-world uptake, pricing dynamics, and SURMOUNT-5 results."
From a data-angled view, Lilly's Q1 2026 results show 56% revenue growth to $19.8B, driven by Mounjaro/Zepbound, while Novo's CER growth was tempered by a $4.2B 340B adjustment reversal that obscures underlying momentum. SURMOUNT-5 head-to-head data strengthen Lilly's case for superior weight-loss efficacy, yet the real test is durable, real-world uptake, payer access, and ongoing pricing dynamics. The advertising lawsuit adds a legal and communications risk that could raise marketing costs or force changes to messaging. The bull case rests on momentum and data; the bear case centers on Novo’s pricing power, new formulations, and potential reversal of one-off 340B benefits.
Strongest counter: the advertising case could constrain Lilly's marketing flexibility, potentially slowing demand. And if SURMOUNT-5 results disappoint or Novo accelerates with Wegovy HD/oral Wegovy, Lilly's apparent lead could evaporate quickly.
"Claude's EPS growth math is incorrect; patent cliffs remain the bigger overlooked 2028+ risk for both names."
Claude's claim that LLY's $35.50–$37.00 2026 EPS guidance implies 156% growth is mathematically false; consensus 2025 EPS sits around $17.40, so the implied growth is roughly 105-113%. This overstatement undercuts the multiple-compression warning. The real unmentioned risk is both firms hitting patent cliffs on legacy products by 2028-2030 while obesity pricing erodes faster than volume grows.
"The real risk is not just EPS growth, but the inevitable margin compression driven by PBM-mandated net price concessions as GLP-1s become standard of care."
Grok is right to correct Claude on the EPS math, but both are missing the elephant in the room: the PBM (Pharmacy Benefit Manager) squeeze. As these drugs move from 'luxury' to 'standard of care,' payers are aggressively forcing net price concessions. We aren't just looking at volume growth; we are looking at a permanent shift in the gross-to-net spread. If LLY and NVO can't offset these rebates with massive volume, their margins will compress regardless of clinical superiority.
"PBM rebate pressure is symmetric, but LLY's valuation premium assumes asymmetric pricing power that may not survive payer consolidation."
Gemini's PBM squeeze is the most underexplored risk here. But it cuts both ways: LLY's scale and pipeline depth give it negotiating leverage NVO lacks. Conversely, if rebate pressure forces both into a margin race, NVO's lower valuation multiple (38x vs. 58x) provides a cushion. The real question: does LLY's clinical edge justify a 53% valuation premium if net pricing power erodes symmetrically? That hasn't been answered.
"Manufacturing ramp risk could overshadow rebates and pricing dynamics, constraining upside through 2028."
Gemini’s PBM squeeze is real, but the bigger, less-discussed risk is Lilly’s ability to scale Tirzepatide/Zepbound production fast enough to meet demand. If supply ramps lag, Lilly sacrifices net price and share to avoid stockouts, while Novo accelerates with oral Wegovy and higher-dose injectables. The margin-and-share risk isn’t just rebates; it’s a capacity constraint that could compress the upside in 2026–28 more than the 340B or messaging headlines imply.
The panelists agree that while Lilly (LLY) has shown impressive growth and superior efficacy in weight loss, the market is overlooking significant risks such as patent cliffs, pricing pressure from PBMs, and supply constraints. Novo Nordisk (NVO) is also facing challenges but has a strong global manufacturing capacity and head start in oral formulations.
LLY's clinical edge and pipeline depth
PBM squeeze and potential erosion of net pricing power